Hologic has a Zacks Rank of #2 (Buy), while Edwards Lifesciences has a Zacks Rank of #3 (Hold) right now. This means that HOLX's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one factor that value investors are interested in. HOLX currently has a forward P/E ratio of 18.26, while EW has a forward P/E of 31.82. We also note that HOLX has a PEG ratio of 2.48. This metric is used similarly to the famous P/ ...

As quoted in a Markets Insider report, the strategist warns that investors' optimism has driven the market to record highs following the U.S. Federal Reserve's recent policy update confirming the rate cut expectations in 2024. In contrast to the investor sentiment, Hussman maintains a bearish outlook, warning of a potential downturn. Citing the dramatic escalation of debt levels since the 2008 crisis, expert Jim Rogers has also voiced concerns about the possibility of a very big correction in the coming mon ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell- side) analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about Hologic (HOLX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Hologic currently has an average brokera ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Hologic (HOLX) .Hologic currently has an average brokerage recomm ...

The Good Brigade In February, I believed that shares of Hologic, Inc. (NASDAQ:HOLX) were starting to look a bit more attractive as headwinds were disappearing. The women's health business benefited greatly from the pandemic (through its diagnostics business) yet the subsequent headwinds are ending in 2024. This improves the prospects for growth as appeal was slowly emerging, with year-over-year growth appearing in the coming quarters. All this looks quite compelling amidst a strong balance sheet, solid trac ...

Did you analyze how Hologic (HOLX) fared in its international operations for the quarter ending March 2024? Given the widespread global presence of this medical device maker, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLOG ...

Hologic, Inc. (NASDAQ:HOLX) Q2 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Steve MacMillan - Chairman, President and Chief Executive Officer Essex Mitchell - Chief Operating Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Casey Woodring - JPMorgan Andrew Brackmann - William Blair Andrew Cooper - Raymond James Opera ...

Exhibit 99.1 Hologic Announces Financial Results for Second Quarter of Fiscal 2024 – Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03; Revenue and Non-GAAP Diluted EPS Exceeded Guidance – – Total Company Organic Revenue Growth Excluding COVID-19 of 4.9% in Constant Currency; Against a 21.9% Prior Year Period Comparable – – Company Raises Full-Year Revenue Midpoint in Constant Currency and Raises EPS Guidance on Strong Margins – MARLBOROUGH, Mass. (May 2, 2024) – Holo ...

Hologic Inc. (HOLX) is set to report second-quarter fiscal 2024 results on May 2, after the closing bell.Strong strategic expansion globally is gaining investors’ confidence in Hologic. The company has been undertaking significant efforts to enter new geographies as many of its best-in-class products command a leading share in the domestic market. The company holds a disproportionately low market share internationally, indicating significant untapped potential. In addition, the continued spree of strategic ...